Europe Spinal Cord Stimulation Device for Chronic Pain Market Forecast to 2030 - Regional Analysis - by Product Type (Rechargeable and Non-Rechargeable), Application (Failed Back Syndrome, Complex Regional Pain Syndrome, Degenerative Disk Disease, and Oth

Europe Spinal Cord Stimulation Device for Chronic Pain Market Forecast to 2030 - Regional Analysis - by Product Type (Rechargeable and Non-Rechargeable), Application (Failed Back Syndrome, Complex Regional Pain Syndrome, Degenerative Disk Disease, and Others), and End User (Hospitals, Ambulatory Surgery Centers, and Others)

The spinal cord stimulation device for chronic pain market was valued at US$ 799.87 million in 2022 and is expected to reach US$ 1,412.01 million by 2030; it is estimated to register at a CAGR of 7.4% from 2022 to 2030. Rehabilitation and Specialized Centers Providing Effective Treatment for Spinal Cord Injuries Fuels Spinal Cord Stimulation Device for Chronic Pain Market According to a report by the NIH, specialized centers of care for SCI were first established in England with an objective to improve the care and neurological recovery of patients. SCI tertiary care centers are developed to improve clinical outcomes and neurological recovery among patients suffering from acute SCIs. Additionally, the Spinal Cord Injury Center at Heidelberg University Hospital in Germany is the only academic center dedicated to the treatment and research of SCIs. The staff at Heidelberg University Hospital, including ~145 staff members, provides treatment to ~1,500 patients suffering from acute or chronic spinal cord injuries annually, among which 1,000 receive outpatient care. Spinal cord stimulation devices are highly adopted in rehabilitation centers. A treatment method based on these devices supports patients physically and psychologically to maximize their neurological recovery and general health in a short time. The Walk Again Center based in Berlin is one such example of a rehabilitation center to treat neurological conditions. This rehab center employs both medicine and technology to treat SCIs. It uses innovative medical procedures, including structural and neural neuroplasticity, where doctors provide therapy to patients suffering from brain damage. Therefore, advanced rehab centers and specialized centers provide growth opportunities to the Europe spinal cord stimulation devices for chronic pain market. Europe Spinal Cord Stimulation Device for Chronic Pain Market Overview Europe spinal cord stimulation device for chronic pain market by region, is segmented as Germany, France, Italy, Spain, United Kingdom, Switzerland, Netherlands, Sweden, and Rest of Europe. The rising healthcare claims and associated costs, increasing administrative transactions, and spinal cord stimulation device for chronic pain platform in supply chain tracking are among the prominent factors propelling the market growth. for instance, in Italy, spinal cord treatments in hospitals are fully covered under insurance through the Italian National Health System (NHS). Therefore, there is high awareness of effective treatments available for SCIs among the Italian population. Therefore, the availability of proper health coverage provisions for SCI signifies a high demand for spinal cord stimulation devices among hospitals and specialty centers in Italy. Europe Spinal Cord Stimulation Device for Chronic Pain Market Revenue and forecast to 2030 (US$ Million) Europe Spinal Cord Stimulation Device for Chronic Pain Market Segmentation The spinal cord stimulation device for chronic pain market is segmented based on product type, application, end user, and country. Based on product type, the spinal cord stimulation device for chronic pain market is bifurcated into rechargeable and non-rechargeable. The rechargeable segment held a larger share in 2022. In terms of application, the spinal cord stimulation device for chronic pain market is segmented into failed back syndrome, complex regional pain syndrome, degenerative disk disease, and others. The complex regional pain syndrome segment held the largest share in 2022. By end user, the spinal cord stimulation device for chronic pain market is segmented into hospitals, ambulatory surgery centers (ASCS), and others. The hospitals segment held the largest share in 2022. Based on country, the spinal cord stimulation device for chronic pain market is categorized into Germany, France, the UK, Spain, Italy, Switzerland, Sweden, Poland, Belgium, Slovakia, Czech Republic, Greece, Ireland, the Netherland, and the Rest of Europe. Germany dominated the spinal cord stimulation device for chronic pain market in 2022. Boston Scientific Corp, Abbott Laboratories, Medtronic Plc, Biotronik SE & Co KG, Nevro Corp, Cirtec Medical Corp, and Synapse Biomedical Inc are some of the leading companies operating in the Europe spinal cord stimulation device for chronic pain market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe spinal cord stimulation device for chronic pain market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe spinal cord stimulation device for chronic pain market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.